• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

依洛尤单抗在孤立性心脏移植的家族性高脂血症中的应用。

Use of Evolocumab in Familial Hyperlipidemia With Isolated Heart Transplant.

作者信息

Mackenzie Colin, Anderson McHale, Shah Kevin S

机构信息

Department of Internal Medicine, University of Utah, Salt Lake City, Utah, USA.

Division of Cardiovascular Medicine, University of Utah, Salt Lake City, Utah, USA.

出版信息

JACC Case Rep. 2024 Aug 7;29(15):102426. doi: 10.1016/j.jaccas.2024.102426.

DOI:10.1016/j.jaccas.2024.102426
PMID:39157565
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11328786/
Abstract

We describe a novel use of evolocumab for successful postoperative lipid control in a patient with familial hyperlipidemia who underwent isolated heart transplantation. We believe that this case carries valuable lessons regarding post-transplant proprotein convertase subtilisin kexin 9 inhibitor use with implications for the future of combined organ allocation and transplantation waitlist times.

摘要

我们描述了依洛尤单抗在一名接受单纯心脏移植的家族性高脂血症患者术后成功控制血脂方面的新用途。我们认为，该病例对于移植后前蛋白转化酶枯草溶菌素9抑制剂的使用具有宝贵的借鉴意义，对未来联合器官分配和移植等待时间也有启示。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/224b/11328786/2c7320fba406/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/224b/11328786/5fb65f71fcbb/ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/224b/11328786/52d9ca50e3eb/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/224b/11328786/2c7320fba406/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/224b/11328786/5fb65f71fcbb/ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/224b/11328786/52d9ca50e3eb/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/224b/11328786/2c7320fba406/gr2.jpg

相似文献

1
Use of Evolocumab in Familial Hyperlipidemia With Isolated Heart Transplant.依洛尤单抗在孤立性心脏移植的家族性高脂血症中的应用。
JACC Case Rep. 2024 Aug 7;29(15):102426. doi: 10.1016/j.jaccas.2024.102426.
2
Plasma proprotein convertase subtilisin/kexin type 9 concentration and recurrent cardiovascular events in patients with familial hypercholesterolemia.家族性高胆固醇血症患者的血浆前蛋白转化酶枯草溶菌素/凝血酶 9 浓度与复发性心血管事件。
Eur J Prev Cardiol. 2021 Apr 23;28(3):272-279. doi: 10.1177/2047487319880985. Epub 2019 Oct 11.
3
Inhibition of Proprotein Convertase Subtilisin/Kexin-9 After Kidney Transplant: Single-Center Experience Among Patients With High Cardiovascular Risk.肾移植后丝氨酸蛋白酶 9/9 抑制剂：高心血管风险患者的单中心经验。
Exp Clin Transplant. 2024 Jan;22(Suppl 1):315-322. doi: 10.6002/ect.MESOT2023.P111.
4
Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitor use in the management of resistant hypercholesterolemia induced by mitotane treatment for adrenocortical cancer.前蛋白转化酶枯草溶菌素 9（PCSK9）抑制剂在治疗肾上腺皮质癌时使用米托坦引起的耐药性高胆固醇血症中的应用。
J Clin Lipidol. 2018 May-Jun;12(3):826-829. doi: 10.1016/j.jacl.2018.03.078. Epub 2018 Mar 13.
5
Evolocumab for the treatment of hypercholesterolemia.依洛尤单抗用于治疗高胆固醇血症。
Expert Opin Biol Ther. 2017 Nov;17(11):1447-1461. doi: 10.1080/14712598.2017.1365134. Epub 2017 Aug 16.
6
12-Week Effectiveness and Safety of Low-Density Lipoprotein Cholesterol-Lowering Therapy by Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition in Patients With Familial Hypercholesterolemia and Hypercholesterolemia　- Data From a Real-World Observational Study of Evolocumab in Japan.前蛋白转化酶枯草溶菌素/克新9型抑制对家族性高胆固醇血症和高胆固醇血症患者低密度脂蛋白胆固醇降低治疗的12周有效性和安全性——来自日本依洛尤单抗真实世界观察性研究的数据
Circ Rep. 2019 May 8;1(5):219-227. doi: 10.1253/circrep.CR-19-0027.
7
Evolocumab: Considerations for the Management of Hyperlipidemia.依洛尤单抗：高血脂管理的考虑因素。
Curr Atheroscler Rep. 2018 Mar 6;20(4):17. doi: 10.1007/s11883-018-0720-3.
8
Evolocumab: A Review in Hyperlipidemia.依洛尤单抗：高脂血症综述
Am J Cardiovasc Drugs. 2016 Feb;16(1):67-78. doi: 10.1007/s40256-015-0153-0.
9
Use of PCSK9 Inhibitors in Solid Organ Transplantation Recipients.前蛋白转化酶枯草溶菌素9（PCSK9）抑制剂在实体器官移植受者中的应用。
JACC Case Rep. 2020 Feb 12;2(3):396-399. doi: 10.1016/j.jaccas.2019.09.026. eCollection 2020 Mar.
10
Preclinical discovery and development of evolocumab for the treatment of hypercholesterolemia.依洛尤单抗治疗高胆固醇血症的临床前发现和开发。
Expert Opin Drug Discov. 2020 Apr;15(4):403-414. doi: 10.1080/17460441.2020.1704728. Epub 2020 Jan 23.

本文引用的文献

1
Dual-Organ Transplantation: Indications, Evaluation, and Outcomes for Heart-Kidney and Heart-Liver Transplantation: A Scientific Statement From the American Heart Association.双器官移植：心脏-肾脏和心脏-肝脏移植的适应症、评估及结果：美国心脏协会科学声明
Circulation. 2023 Aug 15;148(7):622-636. doi: 10.1161/CIR.0000000000001155. Epub 2023 Jul 13.
2
Inclisiran: A New Strategy for LDL-C Lowering and Prevention of Atherosclerotic Cardiovascular Disease.依洛尤单抗：降低 LDL-C 水平和预防动脉粥样硬化性心血管疾病的新策略。
Vasc Health Risk Manag. 2023 Jul 6;19:421-431. doi: 10.2147/VHRM.S338424. eCollection 2023.
3
The International Society for Heart and Lung Transplantation (ISHLT) guidelines for the care of heart transplant recipients.
国际心肺移植学会（ISHLT）心脏移植受者护理指南。
J Heart Lung Transplant. 2023 May;42(5):e1-e141. doi: 10.1016/j.healun.2022.10.015. Epub 2022 Dec 20.
4
2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Solution Set Oversight Committee.2022年美国心脏病学会解决方案集监督委员会关于非他汀类疗法在降低低密度脂蛋白胆固醇以管理动脉粥样硬化性心血管疾病风险中的作用的专家共识决策路径报告。
J Am Coll Cardiol. 2022 Oct 4;80(14):1366-1418. doi: 10.1016/j.jacc.2022.07.006. Epub 2022 Aug 25.
5
Combined heart and liver transplantation: an updated systematic review.心脏肝联合移植：一项更新的系统评价。
Ann R Coll Surg Engl. 2022 Feb;104(2):88-94. doi: 10.1308/rcsann.2021.0103. Epub 2021 Sep 6.
6
The Effect of Mipomersen in the Management of Patients with Familial Hypercholesterolemia: A Systematic Review and Meta-Analysis of Clinical Trials.米泊美生在家族性高胆固醇血症患者管理中的作用：一项临床试验的系统评价和荟萃分析
J Cardiovasc Dev Dis. 2021 Jul 20;8(7):82. doi: 10.3390/jcdd8070082.
7
Use of PCSK9 Inhibitors in Solid Organ Transplantation Recipients.前蛋白转化酶枯草溶菌素9（PCSK9）抑制剂在实体器官移植受者中的应用。
JACC Case Rep. 2020 Feb 12;2(3):396-399. doi: 10.1016/j.jaccas.2019.09.026. eCollection 2020 Mar.
8
PCSK9 Inhibitors in Heart Transplant Patients: Safety, Efficacy, and Angiographic Correlates.心脏移植患者的 PCSK9 抑制剂：安全性、疗效和血管造影相关性。
J Card Fail. 2021 Jul;27(7):812-815. doi: 10.1016/j.cardfail.2021.02.018. Epub 2021 Mar 20.
9
Evinacumab for Homozygous Familial Hypercholesterolemia.依洛尤单抗治疗纯合子家族性高胆固醇血症。
N Engl J Med. 2020 Aug 20;383(8):711-720. doi: 10.1056/NEJMoa2004215.
10
Cholesterol lowering with EVOLocumab to prevent cardiac allograft Vasculopathy in De-novo heart transplant recipients: Design of the randomized controlled EVOLVD trial.依洛尤单抗降低胆固醇以预防心脏移植受者新发心脏移植物血管病的研究（EVOLVD 试验）：一项随机对照试验的设计。
Clin Transplant. 2020 Sep;34(9):e13984. doi: 10.1111/ctr.13984. Epub 2020 Aug 6.